
Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.

Your AI-Trained Oncology Knowledge Connection!


Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.

Benjamin Diamond, MD, discusses the rationale for examining long-term minimal residual disease in patients with multiple myeloma.

Published: May 5th 2021 | Updated:

Published: May 21st 2021 | Updated: